Stereotaxis (STXS)
(Real Time Quote from BATS)
$1.75 USD
-0.04 (-2.24%)
Updated Jul 5, 2024 12:18 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
STXS 1.75 -0.04(-2.24%)
Will STXS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for STXS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for STXS
Stereotaxis (STXS) Gets CE Recertification for Approved Products
Stereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias
STXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stereotaxis (STXS) Inks Deal to Buy Access Point Technologies
Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
Other News for STXS
Hyliion Holdings And 3 Other Penny Stocks Insiders Are Buying
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment
Stereotaxis announces first heart rhythm treatments at Penn Presbyterian
Stereotaxis Receives CE Mark Recertification Under EU’s MDR Regulatory Framework
Stereotaxis receives CE mark recertification under EU’s MDR regulatory framework